• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

12 November 2019

Baqsimi (glucagon), first non-injectable treatment for severe low blood sugar levels


0 Comments3 Minutes

5 November 2019

Reyvow (lasmiditan), new treatment for patients with migraine


0 Comments4 Minutes

4 November 2019

Trikafta (elexacaftor/ivacaftor/tezacaftor), new breakthrough therapy for cystic fibrosis


0 Comments6 Minutes

1 October 2019

Mavyret (glecaprevir and pibrentasvir), a treatment for adults and children with all genotypes of hepatitis C and compensated cirrhosis, shortens the duration of treatment to eight weeks


0 Comments4 Minutes

24 September 2019

Rybelsus (semaglutide), first oral GLP-1 treatment for type 2 diabetes


0 Comments5 Minutes

23 September 2019

Ofev (nintedanib), first treatment for patients with rare type of lung disease


0 Comments5 Minutes

7 September 2019

Nourianz (istradefylline), new add-on drug to treat off episodes in adults with Parkinson’s disease


0 Comments3 Minutes

31 August 2019

Xenleta (lefamulin), new antibiotic to treat community-acquired bacterial pneumonia


0 Comments3 Minutes

22 August 2019

Inrebic (fedratinib) capsules, new treatment for adult patients with certain types of myelofibrosis


0 Comments4 Minutes

17 August 2019

Pretomanid, new drug for the treatment of tuberculosis that affects the lungs


0 Comments3 Minutes

  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com